Furthermore, our strategy of targeting multiple nodes along the ENO1-ATP/lactate-AMPK/PI3K/AKT-mTOR axis via clinically available drugs represents a novel translational approach that bridges laboratory research and clinical treatment for GC. Here, ENO1 is linked to gastric cancer.